FOGHORN THERAPEUTICS INC (FHTX)
Health Care · Precision oncology biotechnology · NASDAQ
Precision biotechnology company developing chromatin-targeting small molecule therapeutics to treat cancer and other serious diseases by correcting abnormal gene expression.
What FOGHORN THERAPEUTICS INC does
Foghorn Therapeutics is a clinical-stage precision therapeutics biotechnology company developing small molecule drugs targeting the chromatin regulatory system, which controls gene expression in cells. The company's proprietary Gene Traffic Control® platform enables discovery and validation of novel targets within chromatin remodeling complexes, transcription factors, and related factors that are dysregulated in cancer and other diseases. Foghorn currently has more than seven programs in development, with FHD-909 (a selective SMARCA2/BRM inhibitor) in Phase 1 clinical trials through a collaboration with Eli Lilly. The company is biology-first in its approach, using protein degraders, allosteric enzymatic inhibitors, and transcription factor disruptors as appropriate for each target.
Themes: ["chromatin regulation / epigenetics","precision oncology","synthetic lethal therapeutics","cancer immunology","SMARCA4-mutated cancers"]
Fundamentals
- Price$6.01 as of 2026-07-09 close
- Market cap$353M as of 2026-07-10
- 1-year return+26.2% as of 2026-07-09 close
- Net margin-266.9% as of 2026-07-10
- ROE-301.6% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+20.1% as of 2026-07-10
- Revenue CAGR (3y)+17.1% SEC XBRL
- Beta2.78 as of 2026-07-10
Key risks (from latest filing)
[]
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.